FABP2 and myeloid sarcoma: We do not know whether the augmented I-FABP concentrations observed in MS are the consequence of functional alterations of the small or of the large intestine; as SCFAs are produced in the large intestine it is nevertheless tempting to hypothesize that such I-FABP increments are the consequence of damages that affect the large intestine as a result of dysbiosis.